These two stocks are poised to crush the market thanks to their outsize growth prospects and dirt cheap valuations.

A new analysis of health data from Ontario, Canada, suggests that nirmatrelvir-ritonavir (Paxlovid) may provide limited benefit for vaccinated older adults with COVID-19, despite its previously proven ...

While the flu is cyclical and can cause different levels of infections from year to year, local doctors suggested that the ...

PFE offers a 6.73% dividend yield and growth potential, driven by strategic acquisitions, R&D, and discounted valuations.

Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research.

The antiviral pill Paxlovid does not significantly reduce COVID-19 hospitalizations in vaccinated older adults, according to ...

Adding a personalized mRNA vaccine to standard treatment could offer new hope for pancreatic cancer patients, a small yet ...

Paxlovid may not decrease the risk for hospitalization or death in older adults vaccinated against COVID-19 as much as ...

Still, Mafi says there aren't strong data on how Paxlovid affects the disease course in people who are vaccinated. His findings suggest that the benefits are about four times smaller than those ...

The authors compared outcomes among adults just under 70 years who were not prescribed Paxlovid to those who were given the ...

The main signs of COVID-19 are respiratory symptoms, like congestion and a cough. But COVID-19 can also cause skin rashes, ...

Veteran vaccine researcher Arturo Casadevall gives a podcast primer on vaccinations, from how they work on a molecular level to common misconceptions ...